Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study

Journal of Renal Nutrition

Volumn 27, Issue 5, 2017, Pages 346-354

  Koiwa, Fumihiko ^a   Yokoyama, Keitaro ^b   Fukagawa, Masafumi ^c   Akizawa, Tadao ^d  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC ION; PARATHYROID HORMONE; PHOSPHORUS; SUCROFERRIC OXYHYDROXIDE; SUCROSE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; JAPAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG COMBINATIONS; FEMALE; FERRIC COMPOUNDS; HUMANS; HYPERPHOSPHATEMIA; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS; SUCROSE; TREATMENT OUTCOME;

EID: 85019542671     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2017.02.007     Document Type: Article

References (20)

1. Block, G.A., Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis). Curr Opin Nephrol Hypertens 10 (2001), 741–747.
2. Block, G.A., Klassen, P.S., Lazarus, J.M., Ofsthun, N., Lowrie, E.G., Chertow, G.M., Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15 (2004), 2208–2218.
3. Palmer, S.C., Hayen, A., Macaskill, P., et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 305 (2011), 1119–1127.
4. Fukagawa, M., Yokoyama, K., Koiwa, F., et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 17 (2013), 247–288.
5. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:4 suppl 3 (2003), S1–S201.
6. Isakova, T., Gutiérrez, O.M., Chang, Y., et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 20 (2009), 388–396.
7. Lopes, A.A., Tong, L., Thumma, J., et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 60 (2012), 90–101.
8. Jablonski, K., Chonchol, M., Management of mineral and bone disorders in chronic kidney disease patients. Kimmel, P.L., Rosenberg, M.E., (eds.) 1st Chronic Renal Disease, 2015, Elsevier, New York, NY, 646–662.
9. Asmus, H.G., Braun, J., Krause, R., et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transpl 20 (2005), 1653–1661.
10. Drüeke, T.B., Lanthanum carbonate as a first-line phosphate binder: the “cons”. Semin Dial 20 (2007), 329–332.
11. Zaichick, S., Zaichick, V., Karandashev, V., Nosenko, S., Accumulation of rare earth elements in human bone within the lifespan. Metallomics 3 (2011), 186–194.
12. Geisser, P., Philipp, E., PA21: a novel phosphate binder of the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol 74 (2010), 4–11.
13. Floege, J., Covic, A.C., Ketteler, M., et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 86 (2014), 638–647.
14. Floege, J., Covic, A.C., Ketteler, M., et al. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transpl 30 (2015), 1037–1046.
15. Koiwa, F., Terao, A., Dose–response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study. Clin Exp Nephrol, 2016, 10.1007/s10157-016-1299-z.
16. Koiwa, F., Yokoyama, K., Fukagawa, M., Terao, A., Akizawa, T., Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomised, open-label, multicentre, 12-week Phase III study. Nephrology 22 (2017), 293–300.
17. Dong, R., Guo, Z.Y., Ding, J.R., Zhou, Y.Y., Wu, H., Gastrointestinal symptoms: a comparison between patients undergoing peritoneal dialysis and hemodialysis. World J Gastroenterol 20 (2014), 11370–11375.
18. Bailie, G.R., Larkina, M., Goodkin, D.A., et al. Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transpl 28 (2013), 2570–2579.
19. Wang, S., Alfieri, T., Ramakrishnan, K., Braunhofer, P., Newsome, B.A., Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. Nephrol Dial Transpl 29 (2014), 2092–2099.
20. Chiu, Y.W., Teitelbaum, I., Misra, M., de Leon, E.M., Adzize, T., Mehrotra, R., Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 4 (2009), 1089–1096.